922 related articles for article (PubMed ID: 18609117)
41. Secretase inhibitors and modulators for Alzheimer's disease treatment.
Tomita T
Expert Rev Neurother; 2009 May; 9(5):661-79. PubMed ID: 19402777
[TBL] [Abstract][Full Text] [Related]
42. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
43. Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease.
Hansson O; Buchhave P; Zetterberg H; Blennow K; Minthon L; Warkentin S
Neurobiol Aging; 2009 Feb; 30(2):165-73. PubMed ID: 17646035
[TBL] [Abstract][Full Text] [Related]
44. Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein gamma-secretase for the treatment of Alzheimer's disease.
Martone RL; Zhou H; Atchison K; Comery T; Xu JZ; Huang X; Gong X; Jin M; Kreft A; Harrison B; Mayer SC; Aschmies S; Gonzales C; Zaleska MM; Riddell DR; Wagner E; Lu P; Sun SC; Sonnenberg-Reines J; Oganesian A; Adkins K; Leach MW; Clarke DW; Huryn D; Abou-Gharbia M; Magolda R; Bard J; Frick G; Raje S; Forlow SB; Balliet C; Burczynski ME; Reinhart PH; Wan HI; Pangalos MN; Jacobsen JS
J Pharmacol Exp Ther; 2009 Nov; 331(2):598-608. PubMed ID: 19671883
[TBL] [Abstract][Full Text] [Related]
45. The experimental Alzheimer's disease drug posiphen [(+)-phenserine] lowers amyloid-beta peptide levels in cell culture and mice.
Lahiri DK; Chen D; Maloney B; Holloway HW; Yu QS; Utsuki T; Giordano T; Sambamurti K; Greig NH
J Pharmacol Exp Ther; 2007 Jan; 320(1):386-96. PubMed ID: 17003227
[TBL] [Abstract][Full Text] [Related]
46. BACE1 in Alzheimer's disease.
Sathya M; Premkumar P; Karthick C; Moorthi P; Jayachandran KS; Anusuyadevi M
Clin Chim Acta; 2012 Dec; 414():171-8. PubMed ID: 22926063
[TBL] [Abstract][Full Text] [Related]
47. APP processing is regulated by cytoplasmic phosphorylation.
Lee MS; Kao SC; Lemere CA; Xia W; Tseng HC; Zhou Y; Neve R; Ahlijanian MK; Tsai LH
J Cell Biol; 2003 Oct; 163(1):83-95. PubMed ID: 14557249
[TBL] [Abstract][Full Text] [Related]
48. Correlations between soluble α/β forms of amyloid precursor protein and Aβ38, 40, and 42 in human cerebrospinal fluid.
Gabelle A; Roche S; Gény C; Bennys K; Labauge P; Tholance Y; Quadrio I; Tiers L; Gor B; Chaulet C; Vighetto A; Croisile B; Krolak-Salmon P; Touchon J; Perret-Liaudet A; Lehmann S
Brain Res; 2010 Oct; 1357():175-83. PubMed ID: 20713025
[TBL] [Abstract][Full Text] [Related]
49. Β-site APP-cleaving enzyme 1 trafficking and Alzheimer's disease pathogenesis.
Tan J; Evin G
J Neurochem; 2012 Mar; 120(6):869-80. PubMed ID: 22171895
[TBL] [Abstract][Full Text] [Related]
50. Increased CSF-BACE 1 activity is associated with ApoE-epsilon 4 genotype in subjects with mild cognitive impairment and Alzheimer's disease.
Ewers M; Zhong Z; Bürger K; Wallin A; Blennow K; Teipel SJ; Shen Y; Hampel H
Brain; 2008 May; 131(Pt 5):1252-8. PubMed ID: 18334538
[TBL] [Abstract][Full Text] [Related]
51. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury.
Ikonomovic MD; Uryu K; Abrahamson EE; Ciallella JR; Trojanowski JQ; Lee VM; Clark RS; Marion DW; Wisniewski SR; DeKosky ST
Exp Neurol; 2004 Nov; 190(1):192-203. PubMed ID: 15473992
[TBL] [Abstract][Full Text] [Related]
52. BACE1 mRNA expression in Alzheimer's disease postmortem brain tissue.
Coulson DT; Beyer N; Quinn JG; Brockbank S; Hellemans J; Irvine GB; Ravid R; Johnston JA
J Alzheimers Dis; 2010; 22(4):1111-22. PubMed ID: 20930286
[TBL] [Abstract][Full Text] [Related]
53. Intracellular trafficking of the β-secretase and processing of amyloid precursor protein.
Chia PZ; Gleeson PA
IUBMB Life; 2011 Sep; 63(9):721-9. PubMed ID: 21834057
[TBL] [Abstract][Full Text] [Related]
54. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
[TBL] [Abstract][Full Text] [Related]
55. A comparative assessment of gamma-secretase activity in transgenic and non-transgenic rodent brain.
Goggi JL; Lewis HD; Mok J; Harrison T; Shearman MS; Atack JR; Best JD
J Neurosci Methods; 2006 Oct; 157(2):246-52. PubMed ID: 16859750
[TBL] [Abstract][Full Text] [Related]
56. Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition.
Abramowski D; Wiederhold KH; Furrer U; Jaton AL; Neuenschwander A; Runser MJ; Danner S; Reichwald J; Ammaturo D; Staab D; Stoeckli M; Rueeger H; Neumann U; Staufenbiel M
J Pharmacol Exp Ther; 2008 Nov; 327(2):411-24. PubMed ID: 18687920
[TBL] [Abstract][Full Text] [Related]
57. Early effects of aluminum chloride on beta-secretase mRNA expression in a neuronal model of beta-amyloid toxicity.
Castorina A; Tiralongo A; Giunta S; Carnazza ML; Scapagnini G; D'Agata V
Cell Biol Toxicol; 2010 Aug; 26(4):367-77. PubMed ID: 20111991
[TBL] [Abstract][Full Text] [Related]
58. Intracellular copper deficiency increases amyloid-beta secretion by diverse mechanisms.
Cater MA; McInnes KT; Li QX; Volitakis I; La Fontaine S; Mercer JF; Bush AI
Biochem J; 2008 May; 412(1):141-52. PubMed ID: 18248325
[TBL] [Abstract][Full Text] [Related]
59. [Therapy of Alzheimer disease].
Kovács T
Neuropsychopharmacol Hung; 2009 Mar; 11(1):27-33. PubMed ID: 19731816
[TBL] [Abstract][Full Text] [Related]
60. Novel heparan sulphate analogues: inhibition of beta-secretase cleavage of amyloid precursor protein.
Patey SJ; Yates EA; Turnbull JE
Biochem Soc Trans; 2005 Nov; 33(Pt 5):1116-8. PubMed ID: 16246059
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
